The Global Veterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient (API) Market was valued at USD 149.7 Million in 2023 and is projected to reach USD 249.3 Million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 8.9% during the forecast period (2024–2029). This robust growth is fueled by the rising global demand for effective ectoparasite control in companion animals, the expansion of the pet care industry, and the increasing adoption of long-acting veterinary pharmaceuticals.

As the animal health sector focuses on advanced parasite management and preventative care, the spotlight is on the key API manufacturers who are driving innovation, ensuring supply chain integrity, and meeting stringent global quality standards. In this blog, we profile the Top 10 Companies in the Veterinary Drug Grade Fluralaner API Industry—a mix of multinational chemical giants, specialized ingredient suppliers, and emerging pharmaceutical innovators shaping the future of veterinary medicine.

Download FREE Sample Report:
Veterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient Market – View in Detailed Research Report

---

🔟 1. Nissan Chemical Corporation

Headquarters: Tokyo, Japan
Key Offering: High-Purity Fluralaner API (Purity ≥98%)

Nissan Chemical is a leading global chemical company and a primary innovator in the development of isoxazoline-class compounds, including Fluralaner. The company holds key patents and possesses advanced synthesis capabilities, supplying high-quality Fluralaner API to major veterinary pharmaceutical companies worldwide.

Strategic Initiatives:

• Pioneering research and development in isoxazoline chemistry

• Strategic partnerships with global animal health corporations for API supply

• Continuous optimization of manufacturing processes for scale and cost-efficiency

---

9️⃣ 2. HIKAL Ltd.

Headquarters: Mumbai, India
Key Offering: Fluralaner API for Oral and Topical Formulations

HIKAL is a prominent Indian player in the pharmaceutical API sector, with a strong focus on complex molecules for the animal health industry. The company’s dedicated manufacturing facilities and expertise in active ingredient synthesis make it a reliable supplier of Fluralaner API.

Strategic Initiatives:

• Investment in compliant manufacturing infrastructure (cGMP)

• Expansion of product portfolio to include related veterinary APIs

---

8️⃣ 3. HuBei Masteam Bio-tech Co., Ltd.

Headquarters: Wuhan, Hubei, China
Key Offering: Fluralaner and other Veterinary Pharmaceutical Intermediates

HuBei Masteam Bio-tech specializes in the research, development, and production of fine chemicals and pharmaceutical intermediates, with a growing focus on veterinary APIs. The company is establishing itself as a key supplier in the Asian market for Fluralaner.

Strategic Initiatives:

• Focus on cost-effective production for competitive pricing

• Strengthening distribution networks across Asia and Europe

---

7️⃣ 4. Jiangsu Rivocean Pharmaceutical Technology Co., Ltd.

Headquarters: Taizhou, Jiangsu, China
Key Offering: High-Purity Fluralaner API (Purity ≥99%)

Jiangsu Rivocean is a technology-driven company focused on the development and manufacturing of advanced pharmaceutical intermediates and APIs. The company has developed sophisticated synthesis routes for Fluralaner, ensuring high yield and purity for its clients.

Strategic Initiatives:

• Emphasis on R&D for process innovation and impurity profiling

• Targeting regulatory approvals in key international markets

Download FREE Sample Report:
Veterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient Market – View in Detailed Research Report

---

6️⃣ 5. Shaanxi Dideu Medichem Co., Ltd. (Dideu Group)

Headquarters: Xi’an, Shaanxi, China
Key Offering: Fluralaner API and Custom Synthesis Services

As part of the larger Dideu Group, Shaanxi Dideu Medichem is a established supplier of pharmaceutical ingredients with a robust portfolio that includes Fluralaner. The company leverages its extensive chemical manufacturing experience to serve the global veterinary market.

Strategic Initiatives:

• Integrated supply chain from raw materials to finished API

• Focus on maintaining consistent quality and supply reliability

---

5️⃣ 6. Zhejiang Gihi Chemicals Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: Fluralaner Technical Material and API

Zhejiang Gihi Chemicals is a specialized manufacturer of agrochemical and veterinary drug intermediates and active ingredients. The company produces Fluralaner that meets the specifications required for the formulation of end-use veterinary products.

Strategic Initiatives:

• Scalable production capacity to meet fluctuating market demand

• Competitive positioning as a volume supplier

---

4️⃣ 7. Hunan Huateng Pharmaceutical Co., Ltd.

Headquarters: Changsha, Hunan, China
Key Offering: Generic APIs, including Fluralaner

Hunan Huateng Pharmaceutical is a rapidly growing company focused on the research, production, and sale of pharmaceutical APIs, with a significant segment dedicated to veterinary health. The company is expanding its footprint in the Fluralaner market as patents expire and generic opportunities arise.

Strategic Initiatives:

• Aggressive pursuit of opportunities in the post-patent market

• Building a diverse portfolio of veterinary APIs

---

3️⃣ 8. Taizhou Crene Biotechnology Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: Fluralaner and other Isoxazoline-based APIs

Taizhou Crene Biotechnology specializes in the development and custom synthesis of complex molecules for pharmaceutical applications. The company’s technical expertise positions it as a strategic partner for clients requiring high-quality Fluralaner API.

Strategic Initiatives:

• Focus on niche and custom synthesis projects

• Investment in analytical capabilities for quality control

---

2️⃣ 9. Other Specialized Chemical Manufacturers (Emerging Players)

Headquarters: Various (India, China, Europe)
Key Offering: Fluralaner API and Intermediate Supply

The market includes several other specialized chemical manufacturers who are developing or have begun production of Fluralaner API. These companies often focus on specific regions or serve as secondary suppliers, contributing to the overall market capacity and competitive landscape.

Strategic Initiatives:

• Entering the market with competitive pricing strategies

• Securing regional regulatory approvals

---

1️⃣ 10. Contract Manufacturing Organizations (CMOs)

Headquarters: Global
Key Offering: Fluralaner API manufacturing and development services

Various global Contract Manufacturing Organizations (CMOs) with expertise in complex organic synthesis are also key players. They partner with veterinary pharmaceutical companies that may not have in-house API manufacturing capabilities, providing end-to-end services from process development to commercial-scale production.

Strategic Initiatives:

• Offering flexible and scalable manufacturing solutions

• Ensuring strict compliance with international regulatory standards (e.g., FDA, EMA)

Get Full Report Here:
Veterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Veterinary Fluralaner API is Driven by Innovation and Accessibility

The Veterinary Drug Grade Fluralaner API market is undergoing a significant transformation. While patented products currently command a major share, the impending patent expiries are set to catalyze a shift towards a more competitive generic market, driving down costs and increasing accessibility for pet owners globally.

📈 Key Trends Shaping the Market:

• Patent Expirations: Key patents for Fluralaner-based products are expiring, opening the door for generic API manufacturers and fostering increased competition.

• Geographic Expansion: Growing pet ownership and awareness of parasiticides in emerging economies across Asia-Pacific and Latin America are creating new growth frontiers.

• Product Innovation: Development of new formulations (e.g., combination drugs with other actives) and delivery methods that require specialized API characteristics.

• Regulatory Stringency: Increasingly rigorous quality and safety standards from agencies like the FDA and EMA are raising the bar for API manufacturers, favoring established, compliant players.

The companies listed above are not only supplying a critical ingredient for animal health—they are enabling the development of next-generation parasiticides that ensure the well-being of companion animals worldwide. Their ability to innovate, scale, and adhere to quality standards will be paramount in shaping the future of this dynamic market.

Get Full Report Here:
Veterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient Market – View in Detailed Research Report